These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 20547101)

  • 1. Immunotherapeutic strategies to combat staphylococcal infections.
    Ohlsen K; Lorenz U
    Int J Med Microbiol; 2010 Aug; 300(6):402-10. PubMed ID: 20547101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MSCRAMM--targeted vaccines and immunotherapy for staphylococcal infection.
    Rivas JM; Speziale P; Patti JM; Höök M
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):223-7. PubMed ID: 15603256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapeutic approaches against Staphylococcus aureus.
    Verkaik NJ; van Wamel WJ; van Belkum A
    Immunotherapy; 2011 Sep; 3(9):1063-73. PubMed ID: 21913829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel targets for antibiotics in Staphylococcus aureus.
    Ohlsen K; Lorenz U
    Future Microbiol; 2007 Dec; 2(6):655-66. PubMed ID: 18041906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Staphylococcus aureus immunotherapy: current status and prospects.
    García-Lara J; Foster SJ
    Curr Opin Pharmacol; 2009 Oct; 9(5):552-7. PubMed ID: 19733119
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination and passive immunisation against Staphylococcus aureus.
    Schaffer AC; Lee JC
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 1():S71-8. PubMed ID: 18757184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for and advances in the development of Staphylococcus aureus prophylactic vaccines.
    Broughan J; Anderson R; Anderson AS
    Expert Rev Vaccines; 2011 May; 10(5):695-708. PubMed ID: 21604989
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Staphylococcal vaccines and immunotherapy: to dream the impossible dream?
    Projan SJ; Nesin M; Dunman PM
    Curr Opin Pharmacol; 2006 Oct; 6(5):473-9. PubMed ID: 16870507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on community-associated MRSA virulence.
    Kobayashi SD; DeLeo FR
    Curr Opin Pharmacol; 2009 Oct; 9(5):545-51. PubMed ID: 19726228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Community-acquired methicillin-resistant Staphylococcus aureus infections.
    Palavecino E
    Clin Lab Med; 2004 Jun; 24(2):403-18. PubMed ID: 15177847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the humoral immune response in BALB/c mice immunized with a naked DNA vaccine anti-methicillin-resistant Staphylococcus aureus.
    Roth DM; Senna JP; Machado DC
    Genet Mol Res; 2006 Aug; 5(3):503-12. PubMed ID: 17117366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The evolution of Staphylococcus aureus.
    Deurenberg RH; Stobberingh EE
    Infect Genet Evol; 2008 Dec; 8(6):747-63. PubMed ID: 18718557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges for a universal Staphylococcus aureus vaccine.
    Proctor RA
    Clin Infect Dis; 2012 Apr; 54(8):1179-86. PubMed ID: 22354924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Staphylococcus aureus, a successful pathogen].
    van den Broek PJ
    Ned Tijdschr Geneeskd; 2003 May; 147(22):1045-8. PubMed ID: 12814014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biologic properties and vaccine potential of the staphylococcal poly-N-acetyl glucosamine surface polysaccharide.
    Maira-Litran T; Kropec A; Goldmann D; Pier GB
    Vaccine; 2004 Feb; 22(7):872-9. PubMed ID: 15040940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Staphylococcus aureus pneumonia: emergence of MRSA in the community.
    Bradley SF
    Semin Respir Crit Care Med; 2005 Dec; 26(6):643-9. PubMed ID: 16388433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted immunotherapy for staphylococcal infections : focus on anti-MSCRAMM antibodies.
    Otto M
    BioDrugs; 2008; 22(1):27-36. PubMed ID: 18215088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical isolates of Staphylococcus aureus from the Arkhangelsk region, Russia: antimicrobial susceptibility, molecular epidemiology, and distribution of Panton-Valentine leukocidin genes.
    Vorobieva V; Bazhukova T; Hanssen AM; Caugant DA; Semenova N; Haldorsen BC; Simonsen GS; Sundsfjord A
    APMIS; 2008 Oct; 116(10):877-87. PubMed ID: 19132981
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology, clinical features and management of infections due to community methicillin-resistant Staphylococcus aureus (cMRSA).
    Gosbell IB
    Intern Med J; 2005 Dec; 35 Suppl 2():S120-35. PubMed ID: 16271056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors associated with methicillin-resistant Staphylococcus aureus infection in patients admitted to the ED.
    Viallon A; Marjollet O; Berthelot P; Carricajo A; Guyomarc'h S; Robert F; Zeni F; Bertrand JC
    Am J Emerg Med; 2007 Oct; 25(8):880-6. PubMed ID: 17920971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.